Drugs.com - Clinical Trials

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Ahmedabad, India, January 22, 2025 Zydus, a leading, discovery-based, global pharmaceutical company today announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic...

Feb 9, 2025 - 22:25
 0
Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Ahmedabad, India, January 22, 2025 Zydus, a leading, discovery-based, global pharmaceutical company today announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic...
Read More

Tags:

Previous Article

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multipl...

Next Article

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letet...

Related Posts

U.S. FDA Grants Orphan Drug Designation to Ariceum Therapeutics’ Proprietary Radiopharmaceutical Cancer Therapy

U.S. FDA Grants Orphan Drug Designation to Ariceum Ther...

Feb 10, 2025  0

Lundbeck’s Potential Treatment Amlenetug for Multiple System Atrophy Receives Fast Track Designation From the FDA

Lundbeck’s Potential Treatment Amlenetug for Multiple S...

Feb 17, 2025  0

Sapience Therapeutics Receives FDA Orphan Drug Designation for ST316, a First-in-Class β-catenin Antagonist, for the Treatment of Familial Adenomatous Polyposis (FAP)

Sapience Therapeutics Receives FDA Orphan Drug Designat...

Feb 9, 2025  0